Please login to the form below
Pegasys
This page shows the latest Pegasys news and features for those working in and with pharma, biotech and healthcare.
Trial data suggest Abivax’ drug may clear latent HIV
Meanwhile, Novartis and Genentech are collaborating on the ACTIVATE trial that combines the former’s HDAC inhibitor Farydak (panobinostat) with Genentech’s Pegasys (pegylated interferon-alpha2a), which could also generate results ... In this case
Latest news
-
CHMP recommends Teva's generic version of Astellas' Advagraf
Finally, both Roche and Janssen got the nod for wider licences for Pegasys (peginterferon) and Zytiga (abiraterone acetate), respectively. ... Hepatitis B drug Pegasys has now been recommended to treat non-cirrhotic paediatric patients who are
-
India denies patent on Pfizer's Xeljanz
Earlier cases have involved Novartis' cancer drug Glivec (imatinib), Roche 's Pegasys (peginterferon alfa-2a) for hepatitis, Merck &Co's asthma treatment Singulair (montelukast), Gilead's HIV drug Viread (tenofovir) and
-
Strong sales in breast cancer lift Roche revenues
for chemotherapy Xeloda (capecitabine) and hepatitis drug Pegasys (peginterferon alfa).
-
Pharma should not ignore India
The list of drugs that have lost exclusivity in India is staggering - and Pegasys - just to name a few.
-
GSK loses patent on Tykerb in India
This year has already seen IP setbacks in India for Novartis' leukaemia drug Glivec (imatinib), Merck &Co's Januvia (sitagliptin) diabetes franchise and Singulair (montelukast), Roche's Pegasys (peginterferon alfa-2a),
More from news
Approximately 1 fully matching, plus 29 partially matching documents found.
Latest Intelligence
-
Building BRICs: pharma's key emerging markets are becoming giants
This follows similar patent defeats in India for Pegasys, Roche's hepatitis drug, Merck's asthma treatment, Singulair, Gilead's Viread (HIV) and Pfizer's Sutent (cancer).
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
Oxford PharmaGenesis
Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
